SynthesisEuropean urology focus2021
Radiation Exposure During Prostatic Artery Embolisation: A Systematic Review and Calculation of Associated Risks.
Synthesis in European urology focus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Trial
- [Prostate artery embolization-2026 update : Technique, evidence, and role in the treatment of benign prostatic hyperplasia].Radiologie (Heidelberg, Germany) · 2026Review
- Current considerations in prostate artery embolisation.CVIR endovascular · 2026Article
- Prostatic Artery Embolization with Cyanoacrylate Glue for Benign Prostatic Hyperplasia: A Systematic Review and Single-arm Meta-analysis of Short-term Outcomes.Interventional radiology (Higashimatsuyama-shi (Japan) · 2026Review
- Photon counting detector CTA for prostate artery embolization pre-procedure planning and intra-procedural guidance.CVIR endovascular · 2025Article
- Variation in Cone Beam Computed Tomography Utilization and Radiation Exposure Associated with Prostatic Artery Embolization on Two Separate Angiography Systems.Journal of clinical medicine · 2024Article
- Article
- Prostate Artery Embolization for Benign Prostatic Hyperplasia.The Journal of urology · 2024Article
- One-year outcomes after prostate artery embolization versus laser enucleation: A network meta-analysis.BJUI compass · 2024Review
- Decoding the complexity of benign prostatic hyperplasia therapies in the PARTEM trial.The Lancet regional health. Europe · 2024Article
- [Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to prostatic hyperplasia].Urologie (Heidelberg, Germany) · 2023Article
- Article
- Use of Virtual Injection Technology for Planning and Guidance of Prostate Artery Embolization.Cardiovascular and interventional radiology · 2022Article
- Center experience and other determinants of patient radiation exposure during prostatic artery embolization: a retrospective study in three Scandinavian centers.European radiology · 2022Article
- Advanced image guidance for prostatic artery embolization - a multicenter technical note.CVIR endovascular · 2021Article
- Prostatic Artery Embolization: Influence of Cone-Beam Computed Tomography on Radiation Exposure, Procedure Time, and Contrast Media Use.Cardiovascular and interventional radiology · 2021Observational
- Reasons to consider prostatic artery embolization.World journal of urology · 2021Review
- Prostatic artery embolization performed in anteroposterior projections versus steep oblique projections: single centre retrospective comparative analysis.CVIR endovascular · 2021Article
- [A (new) revolution in the treatment of benign prostatic hyperplasia? Aqua-ablation and prostate embolization].Der Urologe. Ausg. A · 2020Review
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although evidence supporting the efficacy and safety of prostatic artery embolisation (PAE) is increasing, potential associated risks of ionising radiation in this context remain largely unknown. We systematically reviewed reports on radiation exposure (RE) during PAE in the literature and estimated the risk RE poses using a Monte Carlo dose calculation algorithm. Of 842 studies screened, 22 were included. The overall mean dose area product (DAP) was 181.6 Gy∙cm
Indexed as
Identifiers
32418877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.